Deferasirox Dispersible API
Deferasirox Dispersible Tablets
The chemical name of deferasirox is 4-[3,5-di(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid, which was developed by Novartis Pharmaceuticals in Switzerland. The iron chelator product is the first oral iron reductase approved by the US FDA for routine use. It is approved for use in patients aged ≥ 2 years with chronic iron overload caused by blood transfusion. In Europe, it is recommended as a 6-year-old The above first-line drugs for patients with thalassemia iron overload are currently undergoing clinical research in China; Phase II and III clinical trials and pharmacokinetic studies have shown that they have good safety and tolerability, and can significantly reduce heart, Liver iron loading, easily accepted by patients. At the same time, it also has pharmacological properties such as antifungal (such as Mucor growing in an iron-rich environment), anti-cell proliferation, anti-malarial, anti-oxidative stress damage, and anti-cytotoxic induced apoptosis; it can be used for secondary Treatment of diseases such as hemochromatosis and porphyria cutanea tarda.
Chinese name: 地拉罗司
Chinese alias: 去铁斯若；拉罗司杂质；地拉罗司-D4；地拉罗司(去铁斯若)；4-[3,5-二(2-羟基苯基)-1,2,4-三唑-1-基]苯甲酸
English name: deferasirox
English alias: ICL-670; Exjade; Deferasirox;
CAS number: 201530-41-8
Molecular formula: C21H15N3O4
